1. Amakusa T, Iizuka R, Kuruma I, Uto M. Transfer to cerebrospinal fluid of aniracetam in cerebrovascular disease. Journal of Clinical Therapeutics and Medicines 3: 381–392, 1987
2. Bakhle YS, Vane JR. Pharmacokinetic function of the pulmonary circulation. Physiological Reviews 54: 1007–1045, 1974
3. Brandt R, Meyer J. Binding of Ro 13-5057 and of its pyrrolidinone metabolite to human plasma proteins. F. Hoffmann-La Roche (Basel) data on file. B-84’787; December 20, 1982
4. Collins JM, Dedrick RL. Contribution of lungs to total body clearance: Linear and nonlinear effects. Journal of Pharmaceutical Science 71: 66–70, 1982
5. Guenzi A, Zanetti M, Marini G, Lion P, Federspil G. Relative bioavailability of two new oral dosage forms (tablet /040 and sachet /043) of aniracetam (Ro 13-5057) relative to the 750mg sachet (/041). F. Hoffmann-La Roche (Basel) data on file. B-155’057: 1989a